It is important that adverse events are reported appropriately and in line with regulatory requirements. Depending on the type of project, the procedures for safety reporting and the regulatory timeframe for reporting will differ and the protocol will include appropriate information. In addition, please refer to the UoB Adverse Event Reporting SOP (UoB-AES-SOP-001) (Word - 212 KB).
The has further details on safety reporting for clinical research. Effective as of the 1st Aug 2024, the HRA have also updated the process for how they acknowledge SUSARs, further guidance is available via ' link.